Article thumbnail

Phenotypic characterization of patient dengue virus isolates in BALB/c mice differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome

By Anne Tuiskunen, Maria Wahlström, Jakob Bergström, Philippe Buchy, Isabelle Leparc-Goffart and Åke Lundkvist
Topics: Research
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3170302
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1995). A model to study cytokine profiles in primary and heterologously secondary Dengue-2 virus infections. Acta Virol
  2. (2008). A mouse-passaged dengue virus strain with reduced affinity for heparan sulfate causes severe disease in mice by establishing increased systemic viral loads.
  3. (2009). al: The cellular immune response plays an important role in protecting against dengue virus in the mouse encephalitis model. Viral Immunol
  4. (2006). al: Vascular leakage in severe dengue virus infections: a potential role for the nonstructural viral protein NS1 and complement.
  5. (1999). Azizieh F: Shift from a Th1-type response to Th2-type in dengue hemorrhagic fever. Curr Sci
  6. (2007). Both virus and tumor necrosis factor alpha are critical for endothelium damage in a mouse model of dengue virus-induced hemorrhage.
  7. (2005). BR: Deglycosylation of the NS1 protein of dengue 2 virus, strain 16681: construction and characterization of mutant viruses. Arch Virol
  8. (2005). Cedillo-Barron L: Innate immune responses to dengue virus. Arch Med Res
  9. (1991). CM: Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites.
  10. (2009). Development and validation of real-time one-step reverse transcription-PCR for the detection and typing of dengue viruses.
  11. (2002). DW: Dengue: an escalating problem. BMJ
  12. (1987). EE: Protection of mice against dengue 2 virus encephalitis by immunization with the dengue 2 virus nonstructural glycoprotein NS1.
  13. (2005). et al: A variant in the CD209 promoter is associated with severity of dengue disease. Nat Genet
  14. (2006). et al: Amino acid changes in the recombinant Dengue 3 Envelope domain III determine its antigenicity and immunogenicity in mice. Virus Res
  15. (2003). et al: Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol
  16. (2006). et al: Autoimmune pathogenesis in dengue virus infection. Viral Immunol
  17. (1991). et al: Breakdown of the blood-brain barrier during dengue virus infection of mice.
  18. (2001). et al: Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology
  19. (2008). et al: CLEC5A is critical for dengue-virus-induced lethal disease. Nature
  20. (2000). et al: Cytokine cascade in dengue hemorrhagic fever: implications for pathogenesis. FEMS Immunol Med Microbiol
  21. (2010). et al: Dengue virus 3 clinical isolates show different patterns of virulence in experimental mice infection. Microbes Infect
  22. (1999). et al: Development of a novel mouse model for dengue virus infection. Virology
  23. (1999). et al: Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity.
  24. (1990). et al: Flavivirus genome organization, expression, and replication. Annu Rev Microbiol
  25. (2002). et al: Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology
  26. (2003). et al: Improved molecular detection of dengue virus serotype 1 variants.
  27. (2005). et al: Liver injury and viremia in mice infected with dengue-2 virus. Virology
  28. (2000). et al: Manifestation of thrombocytopenia in dengue-2-virusinfected mice.
  29. (2006). et al: Murine model for dengue virus-induced lethal disease with increased vascular permeability.
  30. (1989). et al: N-terminal domains of putative helicases of flaviand pestiviruses may be serine proteases. Nucleic Acids Res
  31. (1985). et al: Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution. Science
  32. (2004). et al: Structure of the dengue virus envelope protein after membrane fusion. Nature
  33. (1998). et al: Study of Dengue virus infection in SCID mice engrafted with human K562 cells.
  34. (2006). et al: Virulence attenuation of Dengue virus due to augmented glycosaminoglycan-binding affinity and restriction in extraneural dissemination.
  35. (1989). Fletterick RJ: Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses. Virology
  36. (2009). guidelines for diagnosis, treatment, prevention and control – New edition. World Health Organization;
  37. (2007). Histopathological and ultrastructural aspects of mice lungs experimentally infected with dengue virus serotype 2. Mem Inst Oswaldo Cruz
  38. (1995). Indirect immunofluorescence for serological diagnosis of dengue virus infections in Swedish patients. Clin Diagn Virol
  39. (2006). Kumaria R: Circulating levels of tumour necrosis factoralpha & interferon-gamma in patients with dengue & dengue haemorrhagic fever during an outbreak.
  40. Leparc-Goffart I: Phenotypic and genotypic characterization of dengue virus isolates differentiates dengue fever and dengue hemorrhagic fever from dengue shock syndrome.
  41. (1988). Pathogenesis of dengue: challenges to molecular biology. Science
  42. (2009). Rico-Hesse R: Humanized mice show clinical signs of dengue fever according to infecting virus genotype.
  43. (2006). Rico-Hesse R: Models of dengue virus infection. Drug Discov Today Dis Models
  44. (1999). Roehrig JT: New mouse model for dengue virus vaccine testing.
  45. (1995). Shaio MF: Production of cytokines and platelet activating factor in secondary dengue virus infections.
  46. (1997). WHO: Dengue haemorrhagic fever. Diagnosis, treatment, prevention and control.